Your session is about to expire
← Back to Search
Belantamab Mafodotin for Multiple Myeloma (DREAMM-3 Trial)
DREAMM-3 Trial Summary
This trial is testing whether the drug belantamab mafodotin is more effective and has fewer side effects than the standard treatment for relapsed or refractory multiple myeloma.
DREAMM-3 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowDREAMM-3 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 1 trial • 6 Patients • NCT04177823DREAMM-3 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had pneumonitis treated with steroids or have it now.I am currently experiencing bleeding from an internal site.I have symptoms of amyloidosis, POEMS syndrome, or plasma cell leukemia currently.I do not have Hepatitis B, or if I do, I meet the specific criteria for inclusion.I cannot tolerate blood clot prevention treatments.My side effects from previous treatments are mild, except for hair loss and some nerve pain.My liver condition is stable.I am at least 18 years old, or over 19 if I am from the Republic of Korea.I have had a stem cell transplant from a donor.You have specific levels of proteins in your blood and urine that can be measured.I haven't had anti-MM antibody treatment in the last 30 days.I am able to understand and sign the consent form.I have a mild eye surface condition, not severe.I've had at least 2 treatments for myeloma, including lenalidomide and a proteasome inhibitor, but my disease still progressed.I have only multiple myeloma or any other cancer I had has been stable for over 2 years.I can take care of myself and am up and about more than half of my waking hours.I am currently being treated for an infection.My blood counts, liver, and kidney functions are within normal ranges.I have had a stem cell transplant using my own cells and meet specific criteria.I haven't taken any myeloma treatment or experimental drugs recently.I tested positive for hepatitis C recently or at screening.I have multiple myeloma and have had or can't have a stem cell transplant.I have an active kidney condition.I have not had major surgery in the last 4 weeks.I have not undergone plasmapheresis within the last week.I have previously received BCMA-targeted therapy or pomalidomide.I am at risk for heart disease.
- Group 1: Participants receiving pom/dex
- Group 2: Participants receiving Belantamab mafodotin
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How does Belantamab mafodotin typically help patients?
"Belantamab mafodotin offers an opportunity for treatment to patients suffering from ophthalmia, sympathetic, branch retinal vein occlusion, and macular edema."
In how many different healthcare facilities is this research project being undertaken today?
"Currently, there are 16 sites participating in this study; however, the locations closest to you may not be listed. The locations in Plantation, Tucson and Santa Barbara are participating in this study as well as 16 other locations. To minimize travel requirements, if you enroll, it is best to choose the location nearest you."
Are we looking for new participants in this experiment?
"This specific study is no longer looking for patients, as it has already wrapped up recruitment. However, there are 826 other trials currently underway for patients with multiple myeloma and 612 studies involving Belantamab mafodotin that are actively recruiting patients."
Has Belantamab mafodotin received official government sanctioning for use?
"There is both efficacy and safety data from multiple Phase 3 trials available for Belantamab mafodotin, which our team has evaluated to be a safe medication."
What is the enrollment capacity for this clinical trial?
"Presently, this clinical trial is not seeking new participants. It was initially posted on April 2nd, 2020 and was last updated on September 29th, 2020. You may be interested to know that there are 826 trials actively enrolling patients with multiple myeloma and 612 studies for Belantamab mafodotin are also actively recruiting participants."
Could you please tell me if there have been any other research projects conducted that are similar to Belantamab mafodotin?
"The medication known as belantamab mafodotin was first studied in 2002 by the Manitoba Blood & Marrow Transplant Program CancerCare Manitoba. In the years since, there have been a total of 1126 completed trials. As of right now, there are 612 live clinical trials involving this medication, with a large number of them based in Plantation, Florida."
Share this study with friends
Copy Link
Messenger